A pharmaceutical company brought on Christopher Gerardi to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral antihyperglycemic drug used in the management of type 2 diabetes. The alleged economic damages were estimated according to appropriateness and, if so, quantum of lost profits, price erosion, and reasonable royalty elements.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...